These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 28478358)

  • 21. A cost-effectiveness model of escitalopram, citalopram,and venlafaxine as first-line treatment for major depressive disorder in Belgium.
    Demyttenaere K; Hemels ME; Hudry J; Annemans L
    Clin Ther; 2005 Jan; 27(1):111-24. PubMed ID: 15763612
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A retrospective analysis to estimate the healthcare resource utilization and cost associated with treatment-resistant depression in commercially insured US patients.
    Li G; Zhang L; DiBernardo A; Wang G; Sheehan JJ; Lee K; Reutfors J; Zhang Q
    PLoS One; 2020; 15(9):e0238843. PubMed ID: 32915863
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care.
    Sørensen J; Stage KB; Damsbo N; Le Lay A; Hemels ME
    Nord J Psychiatry; 2007; 61(2):100-8. PubMed ID: 17454724
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: a systematic review and meta-analysis.
    Meeker AS; Herink MC; Haxby DG; Hartung DM
    Syst Rev; 2015 Mar; 4():21. PubMed ID: 25874839
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Core discrete event simulation model for the evaluation of health care technologies in major depressive disorder.
    Vataire AL; Aballéa S; Antonanzas F; Roijen LH; Lam RW; McCrone P; Persson U; Toumi M
    Value Health; 2014 Mar; 17(2):183-95. PubMed ID: 24636376
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Successfully treated patients with vortioxetine versus venlafaxine: a simplified cost-effectiveness analysis based on a head-to-head study in Asian patients with major depressive disorder.
    Wang G; Zhao K; Reynaud-Mougin C; Loft H; Ren H; Eriksen HF; Ettrup A
    Curr Med Res Opin; 2020 May; 36(5):875-882. PubMed ID: 31990207
    [No Abstract]   [Full Text] [Related]  

  • 27. Escitalopram: a pharmacoeconomic review of its use in depression.
    Croom KF; Plosker GL
    Pharmacoeconomics; 2003; 21(16):1185-209. PubMed ID: 14594439
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of Electroconvulsive Therapy vs Pharmacotherapy/Psychotherapy for Treatment-Resistant Depression in the United States.
    Ross EL; Zivin K; Maixner DF
    JAMA Psychiatry; 2018 Jul; 75(7):713-722. PubMed ID: 29800956
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Economic evaluation of desvenlafaxine in the treatment of major depressive disorder in Spain].
    Rejas Gutiérrez J; Blanca Tamayo M; Gascón Barrachina J; Armada Peláez B
    Rev Psiquiatr Salud Ment; 2016; 9(2):87-96. PubMed ID: 26475204
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Economic outcomes of eszopiclone treatment in insomnia and comorbid major depressive disorder.
    Snedecor SJ; Botteman MF; Schaefer K; Sarocco P; Barry N; Pickard AS
    J Ment Health Policy Econ; 2010 Mar; 13(1):27-35. PubMed ID: 20571180
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost effectiveness of representatives of three classes of antidepressants used in major depression in the UK.
    Lenox-Smith A; Conway P; Knight C
    Pharmacoeconomics; 2004; 22(5):311-9. PubMed ID: 15061681
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Challenging sequential approach to treatment resistant depression: cost-utility analysis based on the Sequenced Treatment Alternatives to Relieve Depression (STAR(⁎)D) trial.
    Olgiati P; Bajo E; Bigelli M; Montgomery S; Serretti A;
    Eur Neuropsychopharmacol; 2013 Dec; 23(12):1739-46. PubMed ID: 24075716
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Vortioxetine: a new antidepressant to treat depressive episodes].
    Colle R; Corruble E
    Encephale; 2016 Feb; 42(1):48-58. PubMed ID: 26358483
    [TBL] [Abstract][Full Text] [Related]  

  • 34. What to expect from a third step in treatment resistant depression: A prospective open study on escitalopram.
    Souery D; Calati R; Papageorgiou K; Juven-Wetzler A; Gailledreau J; Modavi D; Sentissi O; Pitchot W; Papadimitriou GN; Dikeos D; Montgomery S; Kasper S; Zohar J; Serretti A; Mendlewicz J
    World J Biol Psychiatry; 2015 Oct; 16(7):472-82. PubMed ID: 25535987
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adherence to, and Persistence of, Antidepressant Therapy in Patients with Major Depressive Disorder: Results from a Population-based Study in Italy.
    Di Nicola M; Dell'Osso B; Peduto I; Cipelli R; Pugliese AC; Signorelli MS; Ventriglio A; Martinotti G
    Curr Neuropharmacol; 2023; 21(3):727-739. PubMed ID: 35410606
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects of vortioxetine on cognitive performance in working patients with major depressive disorder: A short-term, randomized, double-blind, exploratory study.
    Baune BT; Sluth LB; Olsen CK
    J Affect Disord; 2018 Mar; 229():421-428. PubMed ID: 29331703
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A retrospective chart review study to quantify the monthly medical resource use and costs of treating patients with treatment resistant depression in the United Kingdom.
    Denee T; Ming T; Waller J; Bailey T; Rajkovic-Hooley O; Middleton-Dalby C; Le HH; Zhang Q; McCrone P; Taylor D
    Curr Med Res Opin; 2021 Feb; 37(2):311-319. PubMed ID: 33253055
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of antidepressants versus active monitoring for mild-to-moderate major depressive disorder: a multisite non-randomized-controlled trial in primary care (INFAP study).
    Rubio-Valera M; Peñarrubia-María MT; Iglesias-González M; Knapp M; McCrone P; Roig M; Sabes-Figuera R; Luciano JV; Mendive JM; Murrugara-Centurión AG; Alonso J; Serrano-Blanco A
    Eur J Health Econ; 2019 Jul; 20(5):703-713. PubMed ID: 30725226
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Economic evaluation of St. John's wort (Hypericum perforatum) for the treatment of mild to moderate depression.
    Solomon D; Adams J; Graves N
    J Affect Disord; 2013 Jun; 148(2-3):228-34. PubMed ID: 23291009
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK.
    Wade AG; Toumi I; Hemels ME
    Curr Med Res Opin; 2005 Apr; 21(4):631-42. PubMed ID: 15899113
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.